← Product Code [CGA](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CGA) · K970707 # ELECT II BLOOD GLUCOSE MONITORING SYSTEM (K970707) _Selfcare, Inc. · CGA · Jun 20, 1997 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CGA/K970707 ## Device Facts - **Applicant:** Selfcare, Inc. - **Product Code:** [CGA](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CGA.md) - **Decision Date:** Jun 20, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1345 - **Device Class:** Class 2 - **Review Panel:** Clinical Chemistry ## Indications for Use The Elect II Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood. The Elect II System is intended for use outside the body (in vitro diagnostic use) by diabetics at home as an aid to monitor the effectiveness of diabetes control. ## Device Story System consists of glucose reagent test strip, amperometric meter, and quality control solution. User inserts test strip into meter; applies fingerstick capillary blood sample to strip. Meter measures electrical current generated by glucose oxidation; current is proportional to glucose concentration. Result displayed in 15 seconds. System calibrated to plasma-equivalent values. Used by diabetics at home for self-monitoring of blood glucose levels to aid in diabetes management. ## Clinical Evidence No clinical data provided; substantial equivalence based on technological characteristics and methodology comparison to predicate devices. ## Technological Characteristics Amperometric glucose meter; glucose oxidase enzymatic biosensor; electrochemical detection. System includes reagent test strips and quality control solution. Calibrated to plasma-equivalent values. 15-second measurement time. ## Regulatory Identification A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma. ## Special Controls *Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9. ## Predicate Devices - Elect Blood Glucose Monitoring System ([K961985](/device/K961985.md)) - Precision Q.I.D. Blood Glucose Monitoring System ([K945887](/device/K945887.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K970707 JUN 20 1997 # 510(k) Summary **Manufacturer:** Selfcare, Inc. 200 Prospect Street Waltham, MA 02154 Telephone: (617) 647-3900 Fax: (617) 647-3939 **Contact Person:** Carol Adiletto **Date:** February 25, 1997 **Device Name:** Elect II Blood Glucose Monitoring System **Common Name:** Blood glucose meter and reagent test strips for blood glucose **Classification (meter/strips):** Class II as per 21 CFR Section 862.1345 Glucose test system; Code 75 CGA (glucose oxidase, glucose) Classification panel - Clinical Chemistry **Classification (control):** Class I as per 21 CFR Section 862.1660, Code 75 JJX (singe analyte control) **Classification (lancets):** Class I as per 21 CFR Section 878.4800, Code 79 FMK (lancet, blood) **Performance Standards:** None established under section 514 **Equivalent Devices:** Elect Blood Glucose Monitoring System (Selfcare, Inc. K961985) Precision Q.I.D. Blood Glucose Monitoring System (Medisense, Inc. K945887) 80 {1} 81 # Product Description: The Elect II Blood Glucose Monitoring System comprises a glucose reagent test strip, a amperometric meter and a quality control solution. The user inserts a test strip in the Elect II Meter and applies a small drop of blood from a fingerstick to the sample point on the strip. The meter measures the electrical current that is generated which is proportional to the concentration of glucose present in the blood sample. The blood glucose result is displayed in 15 seconds. The system is calibrated to give a result equivalent to a plasma value, the measurement used by most clinical laboratories. # Intended Use: The Elect II Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood. The Elect II System is intended for use outside the body (in vitro diagnostic use) by diabetics at home as an aid to monitor effectiveness of diabetes control. # Substantial Equivalence: The Elect II Blood Glucose Monitoring System is similar in technological characteristics, methodology and intended use to the predicate devices listed above. The Elect II System utilizes similar biosensor methodology based on a standard enzymatic methodology employing the enzyme glucose oxidase coupled to an electrochemical detection system to measure glucose levels in whole blood. {2} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 JUN 20 1997 Carol A. Adiletto, M.S. Clinical Director SelfCare, Inc. 200 Prospect Street Waltham, Massachusetts 02154 Re: K970707 Elect II Blood Glucose Monitoring System Regulatory Class: II Product Code: CGA Dated: February 25, 1997 Received: February 26, 1997 Dear Ms. Adiletto: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {3} Selfcare, Inc. Elect II Blood Glucose Monitoring System 510(k) Submission Confidential # Indications for Use Form 510(k) Number (if known): K970707 Device Name: Elect II Blood Glucose Monitoring System Indication for Use: The Elect II Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood. The Elect II System is intended for use outside the body (in vitro diagnostic use) by diabetics at home as an aid to monitor the effectiveness of diabetes control. ![img-0.jpeg](img-0.jpeg) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation Prescription Use ☑ OR Over-The-Counter Use ☐ 04 --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CGA/K970707](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CGA/K970707) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com